Nucl Med Mol Imaging (2011) 45:192–196 DOI 10.1007/s13139-011-0092-x
ORIGINAL ARTICLE
Incidental Focal 18F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria Suk Kyong Cho & Joon Young Choi & Jang Yoo & Miju Cheon & Ji Young Lee & Seung Hyup Hyun & Eun Jeong Lee & Kyung-Han Lee & Byung-Tae Kim
Received: 10 March 2011 / Accepted: 16 June 2011 / Published online: 6 July 2011 # Korean Society of Nuclear Medicine 2011
Abstract Purpose The extent and intensity of 18F-FDG uptake in prostate cancer patients are known to be variable, and the clinical significance of focal 18F-fluorodeoxyglucose (18FFDG) uptake that is incidentally found on positron emission tomography (PET) has not been established. We investigated the clinical significance of incidental focal prostate uptake of 18 F-FDG on PET/computed tomography (CT) and analyzed differential findings on PET/CT between malignant and benign uptake. Methods A total of 14,854 whole-body 18F-FDG PET/CT scans (4,806 that were conducted during cancer screening and 10,048 that were conducted to evaluate suspected or alleged cancer outside of the prostate) were retrospectively reviewed to determine the presence, location, multiplicity and maximum standardized uptake value (SUVmax) of focal prostate uptake and combined calcification. The final diagnosis determined by serum prostate-specific antigen (PSA) level and biopsy was compared with PET findings. Results Incidental focal prostate uptake was observed in 148 of 14,854 scans (1.0 %). Sixty-seven of these 148 subjects who had diagnostic confirmation were selected for further analysis. Prostate cancer was diagnosed in nine of 67 subjects (13.4%). The remaining 58 subjects had no malignancy in the prostate based on normal serum PSA level (n=53), or elevated serum PSA level with a negative biopsy result (n=5). While 84.6% (11/13) of malignant
S. K. Cho : J. Y. Choi (*) : J. Yoo : M. Cheon : J. Y. Lee : S. H. Hyun : E. J. Lee : K.-H. Lee : B.-T. Kim Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135–710, Korea e-mail: [email protected]
uptake was peripherally located in the prostate glands, 60.2% (50/83) of benign uptake was centrally located (p
ORIGINAL ARTICLE
Incidental Focal 18F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria Suk Kyong Cho & Joon Young Choi & Jang Yoo & Miju Cheon & Ji Young Lee & Seung Hyup Hyun & Eun Jeong Lee & Kyung-Han Lee & Byung-Tae Kim
Received: 10 March 2011 / Accepted: 16 June 2011 / Published online: 6 July 2011 # Korean Society of Nuclear Medicine 2011
Abstract Purpose The extent and intensity of 18F-FDG uptake in prostate cancer patients are known to be variable, and the clinical significance of focal 18F-fluorodeoxyglucose (18FFDG) uptake that is incidentally found on positron emission tomography (PET) has not been established. We investigated the clinical significance of incidental focal prostate uptake of 18 F-FDG on PET/computed tomography (CT) and analyzed differential findings on PET/CT between malignant and benign uptake. Methods A total of 14,854 whole-body 18F-FDG PET/CT scans (4,806 that were conducted during cancer screening and 10,048 that were conducted to evaluate suspected or alleged cancer outside of the prostate) were retrospectively reviewed to determine the presence, location, multiplicity and maximum standardized uptake value (SUVmax) of focal prostate uptake and combined calcification. The final diagnosis determined by serum prostate-specific antigen (PSA) level and biopsy was compared with PET findings. Results Incidental focal prostate uptake was observed in 148 of 14,854 scans (1.0 %). Sixty-seven of these 148 subjects who had diagnostic confirmation were selected for further analysis. Prostate cancer was diagnosed in nine of 67 subjects (13.4%). The remaining 58 subjects had no malignancy in the prostate based on normal serum PSA level (n=53), or elevated serum PSA level with a negative biopsy result (n=5). While 84.6% (11/13) of malignant
S. K. Cho : J. Y. Choi (*) : J. Yoo : M. Cheon : J. Y. Lee : S. H. Hyun : E. J. Lee : K.-H. Lee : B.-T. Kim Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135–710, Korea e-mail: [email protected]
uptake was peripherally located in the prostate glands, 60.2% (50/83) of benign uptake was centrally located (p
